HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis
Tóm tắt
To evaluate outcome and toxicity of High-dose methotrexate (HDMTX)-based induction therapy followed by consolidation with conventional systemic chemotherapy and facultative intraventricular therapy (modified Bonn protocol) in patients with primary CNS lymphoma (PCNSL). Between 01/2005 and 12/2013 113 patients with newly diagnosed PCNSL presented at our center; 98 of those qualified for HDMTX based chemotherapy, received a modified Bonn protocol and were included in the analysis. The treatment regimen was based on the “Bonn protocol”, but modified by omission of systemic drugs not able to cross the intact blood brain barrier. Intraventricular therapy was postponed until completion of three induction chemotherapy cycles or was replaced by intrathecal liposomal AraC and rituximab was added to induction from 2010 onwards. Median patient age was 67 years (range 38–83). Complete response/complete response unconfirmed (CR/CRu) was achieved in 59/98 patients (60%), partial response (PR) in 9/98 patients (9%). Twenty-four patients (23%) had progressive disease (PD), 6 (6%) died on therapy. Median progression-free survival (PFS) for all patients was 11.4 months, median overall survival (OS) 29.1 months. A trend to better outcome for intraventricular therapy versus intrathecal liposomal AraC was found in patients < 65 years (HR 0.53 [0.19–1.47] for OS and 0.46 [0.21–1.02] for PFS. Ommaya reservoir infection occurred in 3/33 patients (9%). The data of this single center experience suggest that the outcome with a modified Bonn protocol was comparable to that of the previous regimen, showed fewer Ommaya reservoir infections and may have a trend for better outcome with intraventricular therapy.
Tài liệu tham khảo
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014). CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology, 16(Suppl 4), iv1–i63. https://doi.org/10.1093/neuonc/nou223.
Korfel, A., & Schlegel, U. (2013). Diagnosis and treatment of primary CNS lymphoma. Nature Reviews Neurology, 9(6), 317–327. https://doi.org/10.1038/nrneurol.2013.83.
Nelson, D. F. (1999). Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). Journal of Neuro-Oncology, 43, 241–247.
Abrey, L. E., Yahalom, J., & DeAngelis, L. M. (2000). Treatment for primary CNS lymphoma: The next step. Journal of Clinical Oncology, 18, 519–526.
Thiel, E., Korfel, A., Martus, P., Kanz, L., Griesinger, F., Rauch, M., Röth, A., Hertenstein, B., von Toll, T., Hundsberger, T., Mergenthaler, H. G., Leithäuser, M., Birnbaum, T., Fischer, L., Jahnke, K., Herrlinger, U., Plasswilm, L., Nägele, T., Pietsch, T., Bamberg, M., & Weller, M. (2010). High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncology, 11(11), 1036–1047. https://doi.org/10.1016/S1470-2045(10)70229-1.
Pels, H., Schmidt-Wolf, I. G., Glasmacher, A., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., Vogt-Schaden, M., Egerer, G., Bode, U., Schaller, C., Deckert, M., Fimmers, R., Helmstaedter, C., Atasoy, A., Klockgether, T., & Schlegel, U. (2003). Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of Clinical Oncology, 21, 4489–4495.
DeAngelis, L. M. (2003). Primary central nervous system lymphoma: a curable brain tumor. Journal of Clinical Oncology, 21(24), 4471–4473.
Juergens, A., Pels, H., Rogowski, S., Fliessbach, K., Glasmacher, A., Engert, A., Reiser, M., Diehl, V., Vogt-Schaden, M., Egerer, G., Schackert, G., Reichmann, H., Kroschinsky, F., Bode, U., Herrlinger, U., Linnebank, M., Deckert, M., Fimmers, R., Schmidt-Wolf, I. G., & Schlegel, U. (2010). Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Annals of Neurology, 67, 182–189. https://doi.org/10.1002/ana.21824.
Pels, H., Juergens, A., Glasmacher, A., Schulz, H., Engert, A., Linnebank, M., Schackert, G., Reichmann, H., Kroschinsky, F., Vogt-Schaden, M., Egerer, G., Bode, U., Schaller, C., Lamprecht, M., Hau, P., Deckert, M., Fimmers, R., Bangard, C., Schmidt-Wolf, I. G., & Schlegel, U. (2009). Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: Results of a phase II study. Journal of Neuro-Oncology, 91(3), 299–305. https://doi.org/10.1007/s11060-008-9712-4.
Rubinstein, J. L., His, E. D., Johnson, J. L., Jung, S. H., Nakashima, M. O., Grant, B., Cheson, B. D., & Kaplan, L. D. (2013). Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of Clinical Oncology, 31(25), 3061–3068. https://doi.org/10.1200/JCO.2012.46.9957.
Illerhaus, G., Kasenda, B., Ihorst, G., Egerer, G., Lamprecht, M., Keller, U., Wolf, H. H., Hirt, C., Stilgenbauer, S., Binder, M., Hau, P., Edinger, M., Frickhofen, N., Bentz, M., Möhle, R., Röth, A., Pfreundschuh, M., von Baumgarten, L., Deckert, M., Hader, C., Fricker, H., Valk, E., Schorb, E., Fritsch, K., & Finke, J. (2016). High-dose chemotherapy with autologous haematopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: A prospective, single-arm, phase 2 trial. Lancet Haematology, 3(8), e388–e397. https://doi.org/10.1016/S2352-3026(16)30050-3.
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., Reiner, A. S., Panageas, K., Karimi, S., Curry, R., Shah, G., Abrey, L. E., DeAngelis, L. M., & Omuro, A. (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of Clinical Oncology, 31(31), 3971–3979. https://doi.org/10.1200/JCO.2013.50.4910.
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosée, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Sønderskov Gørløv, J., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S. W., Schmoll, H. J., Hertenstein, B., Rummel, M., Smith, J., Pfreundschuh, M., Cabras, G., Angrilli, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., & Illerhaus, G. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology, 4(11), e510–e523. https://doi.org/10.1016/S2352-3026(17)30174-6.
Houillier, C., Taillandier, L., Lamy, T., Chinot, O., Molucon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., Damaj, G., Thyss, A., Jaccard, A., Delwail, V., Gyan, E., Sanhes, L., Cornillon, J., Garidi, R., Delmer, A., Savignoni, A., Jijakli, A., Morel, P., Bourquard, P., Moles, M., Deconinck, E., Morel, P., Gastinne, T., Constans, J., Langer, A., Lacomblez, L., Delgadillo, D., Dureau, S., Turbiez, I., Plissonnier, A., Cassoux, N., Touitou, V., Ricard, D., Hoang-Xuan, K., & Soussain, C. (2016). Whole brain radiotherapy (WBRT) versus intensive chemotherapy with Haematopoietic stem cell rescue (IC + HCR) for primary central nervous system lymphoma (PCNSL) in young patients: An intergroup Anocef-Goelams randomized phase II trial (PRECIS). Blood, 128(22), 782.
Yule, S. M., Price, L., Pearson, A. D., & Boddy, A. V. (1997). Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clinical Cancer Research, 3(11), 1985–1992.
Ferreri, A. J., Guerra, E., Regazzi, M., Pasini, F., Ambrosetti, A., Pivnik, A., Gubkin, A., Calderoni, A., Spina, M., Brandes, A., Ferrarese, F., Rognone, A., Govi, S., Dell'Oro, S., Locatelli, M., Villa, E., & Reni, M. (2004). Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. British Journal of Cancer, 90(2), 353–358.
Birnbaum, T., Stadler, E. A., von Baumgarten, L., & Straube, A. (2012). Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. Journal of Neuro-Oncology, 109(2), 285–291. https://doi.org/10.1007/s11060-012-0891-7.
Holdhoff, M., Ambady, P., Abdelaziz, A., Sarai, G., Bonekamp, D., Blakeley, J., Grossman, S. A., & Ye, X. (2014). High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology, 83(3), 235–239. https://doi.org/10.1212/WNL.0000000000000593.
Rubinstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., O'Brien, J., Haqq, C., & Shuman, M. (2007). Phase 1 study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. Journal of Clinical Oncology, 25(11), 1350–1356.
Ott, R. J., Brada, M., Flower, M. A., Babich, J. W., Cherry, S. R., & Deehan, B. J. (1991). Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. European Journal of Cancer, 27(11), 1356–1361.
Pulczynski, E. J., Kuittinen, O., Erlanson, M., Hagberg, H., Fosså, A., Eriksson, M., Nordstrøm, M., Østenstad, B., Fluge, Ø., Leppä, S., Fiirgaard, B., Bersvendsen, H., & Fagerli, U. M. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica, 100(4), 534–540. https://doi.org/10.3324/haematol.2014.108472.
Glantz, M. J., Cole, B. F., Recht, L., Akerley, W., Mills, P., Saris, S., Hochberg, F., Calabresi, P., & Egorin, M. J. (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? Journal of Clinical Oncology, 16(4), 1561–1567.
Bleyer, W. A., Poplack, D. G., & Simon, R. M. (1978). "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood, 51(5), 835–842.
Küker, W., Nägele, T., Thiel, E., Weller, M., & Herrlinger, U. (2005). Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology, 65(7), 1129–1131.
World Health Organization. (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48 Geneva, Switzerland.
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002). Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10. Journal of Clinical Oncology, 20(24), 4643–4648.
Poortmans, P. M., Kluin-Nelemans, H. C., Haaxma-Reiche, H., Van't Veer, M., Hansen, M., Soubeyran, P., Taphoorn, M., Thomas, J., Van den Bent, M., Fickers, M., Van Imhoff, G., Rozewicz, C., Teodorovic, I., & van Glabbeke, M. (2003). High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Journal of Clinical Oncology, 21(24), 4483–4488.
Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G. M., Avvisati, G., Balzarotti, M., Brandes, A. A., Fajardo, J., Gomez, H., Guarini, A., Pinotti, G., Rigacci, L., Uhlmann, C., Picozzi, P., Vezzulli, P., Ponzoni, M., Zucca, E., Caligaris-Cappio, F., & Cavalli, F. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet, 374, 1512–1520. https://doi.org/10.1016/S0140-6736(09)61416-1.
Omuro, A., Chinot, O., Taillandier, L., Ghesquieres, H., Soussain, C., Delwail, V., Lamy, T., Gressin, R., Choquet, S., Soubeyran, P., Huchet, A., Benouaich-Amiel, A., Lebouvier-Sadot, S., Gyan, E., Touitou, V., Barrié, M., del Rio, M. S., Gonzalez-Aguilar, A., Houillier, C., Delgadillo, D., Lacomblez, L., Tanguy, M. L., & Hoang-Xuan, K. (2015). Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematology, 2(6), e251–e259. https://doi.org/10.1016/S2352-3026(15)00074-5.
Doolittle, N. D., Korfel, A., Lubow, M. A., Schorb, E., Schlegel, U., Rogowski, S., Fu, R., Dósa, E., Illerhaus, G., Kraemer, D. F., Muldoon, L. L., Calabrese, P., Hedrick, N., Tyson, R. M., Jahnke, K., Maron, L. M., Butler, R. W., & Neuwelt, E. A. (2013). Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology, 81(1), 84–92. https://doi.org/10.1212/WNL.0b013e318297eeba.
Roth, P., Martus, P., Kiewe, P., Möhle, R., Klasen, H., Rauch, M., Röth, A., Kaun, S., Thiel, E., Korfel, A., & Weller, M. (2012). Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012, 79(9), 890–896. https://doi.org/10.1212/WNL.0b013e318266fcb2.
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Möhle, R., Löw, S., Binder, M., Atta, J., Keller, U., Wolf, H. H., Krause, S. W., Heß, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Röth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J., & Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31(4), 846–852. https://doi.org/10.1038/leu.2016.334.
Mendez, J. S., Ostrom, Q. T., Gittleman, H., Kruchko, C., DeAngelis, L. M., Barnholtz-Sloan, J. S., & Grommes, C. (2018). The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 20(5), 687–694. https://doi.org/10.1093/neuonc/nox187.